SCHEMBL7456969

SCHEMBL7456969

CCOc1cncc(C=CC(=O)OC(C)(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.49
CHRNB4 P30926 1/20 0.49
CHRNA3 P32297 1/20 0.49
CHRNA7 P36544 1/20 0.49
CHRNA4 P43681 1/20 0.49
KDM4E B2RXH2 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 2/20 0.43
KMT2A Q03164 2/20 0.38
ESR1 P03372 1/20 0.37
SLC5A1 P13866 1/20 0.37
SLC5A2 P31639 1/20 0.37
AKT1 P31749 3/20 0.36
MAOB P27338 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
DYRK3 O43781 2/20 0.36
ROCK2 O75116 2/20 0.36
PRKD3 O94806 2/20 0.36
MAP4K4 O95819 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7456965 1.00 CHRNB2 (0.49) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL25453025 0.90 AKT1 (0.40) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL30192330 0.82 AKT1 (0.37) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL3860495 0.82 KDM4E (0.62) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL3860493 0.82 KDM4E (0.62) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL19244277 0.80 KDM4E (0.68) KDM4ESMN1; SMN2ALDH1A1KMT2AMAOB
SCHEMBL19244276 0.80 KDM4E (0.68) KDM4ESMN1; SMN2ALDH1A1KMT2AMAOB
SCHEMBL19244371 0.79 NPC1 (0.57) KDM4ESMN1; SMN2ALDH1A1KMT2ASLC5A1
SCHEMBL19244373 0.79 NPC1 (0.57) KDM4ESMN1; SMN2ALDH1A1KMT2ASLC5A1
SCHEMBL29985733 0.78 PADI4 (0.38) KDM4ESMN1; SMN2ALDH1A1KMT2AESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6268378-B1 TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH. MERCK & CO., INC. 2001-07-31 US disclosed
EP-1040111-A1 INTEGRIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2000-10-04 EP disclosed
US-6066648-A USEFUL IN INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH MERCK & CO., INC. (US) 2000-05-23 US disclosed
US-6017926-A Integrin receptor antagonists MERCK & CO., INC. (US) 2000-01-25 US disclosed
WO-1999031099-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1999-06-24 WO disclosed